Germ line tumor-associated immunoglobulin VH region peptides provoke a tumor-specific immune response without altering the response potential of normal B cells

Blood

Volumn 104, Issue 3, 2004, Pages 752-759

  Lou, Qiang ^b   Kelleher Jr , Raymond J ^b   Sette, Alessandro ^b   Loyall, Jenni ^b   Southwood, Scott ^b   Bankert, Richard B ^b   Bernstein, Steven H ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CANCER VACCINE; DEXTRAN; EPITOPE; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GERM LINE; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR IMMUNITY;

EID: 3242756746     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0105     Document Type: Article

References (62)

1. Kobrin CB, Kwak LW. Development of vaccine strategies for the treatment of B-cell malignancies. Cancer Invest. 1997;15:577-587.
2. Yancopoulos GD, Alt FW. Regulation of the assembly and expression of variable-region genes. Annu Rev Immunol. 1986;4:339-368.
3. Alt FW, Baltimore D. Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci U S A. 1982;79:4118-4122.
4. Sanz I. Multiple mechanisms participate in the generation of diversity of human H chain CDR3 regions. J Immunol. 1991;147:1720-1729.
5. Flalkow PJ, Klein E, Klein G, Clifford P, Singh S. Immunoglobulin and glucose-6-phosphate dehydrogenase as markers of cellular origin in Burkitt lymphoma. J Exp Med. 1973;138:89-102.
6. Preud'homme JL, Seligmann M. Surface bound immunoglobulins as a cell marker in human lymphoproliferative diseases. Blood. 1972;40:777-794.
7. Stevenson GT, Stevenson FK. Antibody to a molecularly defined antigen confined to a tumour cell surface. Nature. 1975;254:714-716.
8. Ghosh SK, Wong J, Bankert RB. Idiotype-specific T lymphocytes responsible for the selection of somatic variants of a B cell hybrid. J Immunol. 1987;138:2230-2235.
9. Ghosh SK, Bankert RB. Generation of somatic variants of a B cell hybrid mediated by a non-cytolytic L3T4+ idiotype-specific T cell. J Immunol. 1989;142:409-415.
10. Ghosh SK, White LM, Ghosh R, Bankert RB. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype. J Immunol. 1990;145:365-370.
11. Kwak LW, Campbell MJ, Zelenetz AD, Levy R. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin. Blood. 1990;76:2411-2417.
12. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood. 1997;89:3129-3135.
13. Kwak LW, Young HA, Pennington RW, Weeks SD. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc Natl Acad Sci U S A. 1996;93:10972-10977.
14. Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5:1171-1177.
15. Stevenson FK, Zhu D, King CA, Ashworth LJ, Kumar S, Hawkins RE. Idiotypic DNA vaccines against B-cell lymphoma. Immunol Rev. 1995;145:211-228.
16. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses In patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327:1209-1215.
17. Jorgensen T, Gaudernack G, Hannestad K. Immunization with the light chain and the VL domain of the isologous myeloma protein 315 inhibits growth of mouse plasmacytoma MOPC315. Scand J Immunol. 1980;11:29-35.
18. Lauritzsen GF, Weiss S, Bogen B. Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol. 1993;37:77-85.
19. Sugai S, Palmer DW, Talal N, Witz IP. Protective and cellular immune responses to idiotypic determinants on cells from a spontaneous lymphoma of NZB-NZW F1 mice. J Exp Med. 1974;140:1547-1558.
20. Stevenson FK, Gordon J. Immunization with idiotypic immunoglobulin protects against development of B lymphocytic leukemia, but emerging tumor cells can evade antibody attack by modulation. J Immunol. 1983;130:970-973.
21. George AJ, Tutt AL, Stevenson FK. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J Immunol. 1987;138:628-634.
22. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J Immunol. 1990;145:1029-1036.
23. Tani K, Murphy WJ, Chertov O, et al. Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int Immunol. 2000;12:691-700.
24. Timmerman JM, Caspar CB, Lambert SL, Syrengelas AD, Levy R. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood. 2001;97:1370-1377.
25. Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 2002;99:1517-1526.
26. Davis TA, Hsu FJ, Caspar CB, et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B-cell lymphoma. Biol Blood Marrow Transplant. 2001;7:517-522.
27. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52-58.
28. Bahler DW, Campbell MJ, Hart S, Miller RA, Levy S, Levy R. Ig VH gene expression among human follicular lymphomas. Blood. 1991;78:1561-1568.
29. Lossos IS, Okada CY, Tibshirani R, et al. Molecular analysis of immunoglobulin genes in diffuse large B-cell lymphomas. Blood. 2000;95:1797-1803.
30. Trojan A, Schultze JL, Witzens M, et al. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med. 2000;6:667-672.
31. Eyerman MC, Zhang X, Wysocki LJ. T cell recognition and tolerance of antibody diversity. J Immunol. 1996;157:1037-1046.
32. Eyerman MC, Wysocki L. T cell recognition of somatically-generated Ab diversity. J Immunol. 1994;152:1569-1577.
33. Zaghouani H, Krystal M, Kuzu H, et al. Cells expressing an H chain Ig gene carrying a viral T cell epitope are lysed by specific cytolytic T cells. J Immunol. 1992;148:3604-3609.
34. + T cells by a self-derived peptide. Nature. 1995;378:295-298.
35. Wysocki LJ, Zhang X, Smith DS, Snyder CM, Bonorino C. Somatic origin of T-cell epitopes within antibody variable regions: significance to monoclonal therapy and genesis of systemic autoimmune disease. Immunol Rev. 1998;162:233-246.
36. Schepart BS, Abu-Hadid M, Mayers GL, Bankert RB. Antibody response of BALB/c mice to dextran B1355S: alterations in the expression of an idiotype associated with the depletion of idiotype-binding cells. J Immunol. 1985;135:1690-1697.
37. Abu-Hadid MM, Bankert RB, Mayers GL. Selective elimination of idiotype-binding cells in vivo by a drug-idiotype conjugate demonstrates the functional significance of these cells in immune regulation. Proc Natl Acad Sci U S A. 1988;85:3990-3994.
38. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature. 1992;356:443-446.
39. Sidney J, Southwood S, Oseroff C, et al. Measurement of MHC/peptide interactions by gel filtration. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, and Strober W, eds. Current Protocols in Immunology. New York, NY: John Wiley & Sons; 1998;18.3.1-18.3.19.
40. Egilmez NK, Cuenca R, Yokota SJ, Sorgi F, Bankert RB. In vivo cytokine gene therapy of human tumor xenografts in SCID mice by liposome-mediated DNA delivery. Gene Ther. 1996;3:607-614.
41. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152:163-175.
42. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41:178-228.
43. Sette A, Buus S, Appella E, et al. Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A. 1989;86:3296-3300.
44. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77-92.
45. Asai T, Storkus WJ, Whiteside TL. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin Diagn Lab Immunol. 2000;7:145-154.
46. Ma C, Whiteley PE, Cameron PM, et al. Role of APC in the selection of immunodominant T cell epitopes. J Immunol. 1999;163:6413-6423.
47. Adorini L, Appella E, Doria G, Nagy ZA. Mechanisms influencing the immunodominance of T cell determinants. J Exp Med. 1988;168:2091-2104.
48. Sloan VS, Cameron P, Porter G, et al. Mediation by HLA-DM of dissociation of peptides from HLADR. Nature. 1995;375:802-806.
49. Shastri N, Gammon G, Horvath S, Miller A, Sercarz EE. The choice between two distinct T cell determinants within a 23-amino acid region of lysozyme depends on their structural context. J Immunol. 1986;137:911-915.
50. Mo AX, van Lelyveld SF, Craiu A, Rock KL. Sequences that flank subdominant and cryptic epitopes influence the proteolytic generation of MHC class I-presented peptides. J Immunol. 2000;164:4003-4010.
51. Singh RR, Kumar V, Ebling FM, et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med. 1995;181:2017-1027.
52. Sette A, Buus S, Colon S, Miles C, Grey HM. Structural analysis of peptides capable of binding to more than one la antigen. J Immunol. 1989;142:35-40.
53. Zugel U, Wang R, Shih G, Sette A, Alexander J, Grey HM. Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues. J Immunol. 1998;161:1705-1709.
54. Harig S, Witzens M, Krackhardt AM, et al. Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues. Blood. 2001;98:2999-3005.
55. Sette A, Sidney J. Nine major HLA class I super-types account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics. 1999;50:201-212.
56. + tumor-infiltrating lymphocytes in human solid tumors. Immunol Res. 1995;14:119-131.
57. + T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol. 2000;165:6047-6055.
58. Doenecke A, Winnacker EL, Hallek M. Rapid amplification of cDNA ends (RACE) improves the PCR-based isolation of immunoglobulin variable region genes from murine and human lymphoma cells and cell lines. Leukemia. 1997;11:1787-1792.
59. Snyder CM, Zhang X, Wysocki LJ. Negligible class II MHC presentation of B cell receptor-derived peptides by high density resting B cells. J Immunol. 2002;168:3865-3873.
60. Fan GC, Singh RR. Vaccination with minigenes encoding V(H)-derived major histocompatibility complex class 1-binding epitopes activates cytotoxic T cells that ablate autoantibody-producing B cells and inhibit lupus. J Exp Med. 2002;196:731-741.
61. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
62. Tangri S, Ishioka GY, Huang X, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med. 2001;194:833-846.